Inspire Medical Systems Azioni (NYSE: INSP)

Ultime notizie per Inspire Medical Systems (NYSE:INSP) Azioni

Inspire Medical Systems

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems Inc

Inspecs Group PLC

Insperity Inc

Inspira Technologies Oxy B.H.N. Ltd. - Ordinary Shares

Inspira Technologies Oxy BHN Ltd

Inspira Technologies Oxy B.H.N. Ltd. - Warrant

Inspirato Inc

Inspirato Incorporated - Class A Common Stock

Inspire 100 ETF

Inspire Corporate Bond ETF

Inspire Global Hope ETF

Inspire International ETF

INSPIRE SEMICONDUCTOR HLD by INSPIRE SEMICONDUCTOR HLDGS INC.

Inspire Semiconductor Holdings Inc

Inspire Small/Mid Cap ETF

Inspire Tactical Balanced ETF

Inspire Veterinary Partners, Inc. - Class A Common Stock

Inspire Veterinary Partners Inc

InspireMD Inc

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment Inc

News

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.

Needham Reiterates Buy on Equifax, Maintains $350 Price Target

Needham analyst Mike Matson downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.

Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

<a href="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/" title="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/">https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/</a>

Tech

AAPL

Reported Earlier, Apple's New iPhone Sales In China Rose 20% In First 3 Weeks

EV <a href="https://www.benzinga.com/news/24/10/41223011/rivians-production-guidance-cut-spurred-by-miscommunication-with-atlanta-based-supplier-resulting-in">startup</a> Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) said on Thursday that it will launch its Halloween software update starting Oct. 18, complete with spooky features and car costumes.
What Happened: The company announced the update in a video posted on social media platform X featuring actor David Hasselhoff who starred in the Knight Rider series.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">An iconic duo reunited <a href="https://twitter.com/DavidHasselhoff?ref_src=twsrc%5Etfw">@DavidHasselhoff</a>.⁰ The countdown is on. Our Halloween software update arrives after the clock strikes midnight (local). Spooky features will be available for a limited time. <a href="https://t.co/hdKV0z4WIC">pic.twitter.com/hdKV0z4WIC</a>
&mdash; Rivian (@Rivian) <a href="https://twitter.com/Rivian/status/1846945663860572411?ref_src=twsrc%5Etfw">October 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
One of the car costumes available with the update is inspired by Knight Rider. The costume will alter the Rivian&#8217;s interior display system and the exterior lightbar on Gen 2 R1 vehicles will cascade a red beam to replicate the experience of K.I.T.T, the robotic automobile that featured in the series.
There are also other car costumes available with the update, inspired by iconic and classic vehicles from pop culture, such as one inspired by the time machine in Universal Pictures and Amblin Entertainment's Back to the Future, in addition to a spooky option. 
The haunted Rivian car costume has eight different sound effects and three different color themes to choose from ranging between purple, yellow, red, and green. The interior display screen will feature static and ghosts to increase the spooky feeling when the vehicle is parked with the costume. 
Besides Costumes: Besides costumes, Rivian&#8217;s new update changes pedestrians on the driver display to zombies and bicyclists and motorcyclists into headless horsemen. 
Vehicle owners can also play multiple spooky chirp sounds, including one resembling the owl. 
However, the spooky features will only be available for a limited time until November 4, the company warned. Additionally, <a href="https://www.benzinga.com/news/24/08/40574576/rivian-or-lucid-which-of-the-two-loss-making-ev-startups-is-solving-cash-burn">both the vehicle</a> and the Rivian mobile app must be updated to their latest versions for the features, it added.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau" target="_blank" rel="noreferrer noopener">Elon Musk Says SpaceX's Next-Generation Starlink Satellites Will Be ‘So Big That Only Starship Can Launch Them'</a></li>
</ul>
Photo courtesy: Rivian

RIVN

Trick Or Treat: Rivian Rolls Out Spooky Halloween Update Featuring Car Costumes, Creepy Chirps

CNH Industrial, Parsons and more join S&P MidCap 400

Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of $270...

Lake Street Sticks to Their Buy Rating for Inspire Medical Systems (INSP)

Leerink Partners analyst Mike Kratky maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price target ...

Wearable Tech in OSA Treatment: Balancing Market Potential and Uncertainties

Fidelity Select Health Care Portfolio Q2 2024 Review

In a report released today, Richard Newitter from Truist Financial reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report), wit...

Inspire Medical Systems (INSP) Gets a Buy from Truist Financial

Analyst Michael Sarcone of Jefferies assigned a Buy rating on Inspire Medical Systems (INSP – Research Report), with a price target of $230.00. Mic...

Inspire Medical Systems: Poised for Growth with Inspire 5 Launch and Positive Clinical Outcomes

Lazard U.S. Small Cap Equity Select Portfolio Q2 2024 Commentary

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Acadia Healthcare (ACHC – Research Report), Aquestive Therapeutic...

Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novo Nordisk (NVO – Research Report), Inspire Medical Systems (IN...

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Inspire Medical Systems (INSP) and Precigen (PGEN)

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) on October 8 and set a price ta...

Comments

Inspire Medical Systems

Notizie

Ultime notizie per Inspire Medical Systems (NYSE:INSP) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO